Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III studyRobert L. Ferris, Lisa Licitra, Robert I. Haddad et al.|Annals of Oncology|2020Cited by 365
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapyDan P. Zandberg, Ricard Mesı́a, Jill Gilbert et al.|European Journal of Cancer|2018Cited by 267
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trialJ. Guigay, Franck Darloy, Anne Aupérin et al.|The Lancet Oncology|2021Cited by 231
Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and NeckRobert I. Haddad, Deborah Jean Lee Wong, Jérôme Fayette et al.|JAMA|2025Cited by 42
EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).Lisa Licitra, Robert L. Ferris, Robert I. Haddad et al.|Journal of Clinical Oncology|2019Cited by 39